Oncolytic measles virus strains as novel anticancer agents

Expert Opinion on Biological Therapy

Volumn 13, Issue 4, 2013, Pages 483-502

  Msaouel, Pavlos ^a   Opyrchal, Mateusz ^b   Domingo Musibay, Evidio ^b   Galanis, Evanthia ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Cancer gene therapy; Cell carriers; Measles virus; MV NIS; Oncolytic virotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE PHOSPHATE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MEASLES VACCINE; SODIUM IODIDE SYMPORTER; UNCLASSIFIED DRUG; ZAGREB; ONCOLYTIC VIRUS;

ANAPLASTIC THYROID CANCER; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BILE DUCT CARCINOMA; BREAST CANCER; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; CYTOPATHOGENIC EFFECT; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; FIBROSARCOMA; GENE EXPRESSION; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNITY; IMMUNOMODULATION; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LEUKEMIA; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER SARCOMA; LUNG METASTASIS; LYMPHOMA; MEASLES VIRUS; MEDULLOBLASTOMA; MELANOMA; MESOTHELIOMA; MULTIPLE MYELOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PLEURA MESOTHELIOMA; PROSTATE CANCER; REPORTER GENE; REVIEW; TRANSGENE; UVEA MELANOMA; VIRUS STRAIN; ADMINISTRATION AND DOSAGE; ANIMAL; DRUG EFFECTS; GENE VECTOR; GENETICS; NEOPLASMS; PROCEDURES; VIRUS REPLICATION;

MEASLES VIRUS;

ANIMALS; ANTINEOPLASTIC AGENTS; GENETIC VECTORS; HUMANS; MEASLES VACCINE; MEASLES VIRUS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VIRUS REPLICATION;

EID: 84879583055     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.749851     Document Type: Review

References (167)

1. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007;4(2):101-17
2. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012;30(7):658-70
3. Hernandez SA. Observacion de un caso de enfermedad de Hodgkin, con regresion de los sintomas e infartos ganglionares. post-sarampion. Arch Cubanos Cancer 1949;8:26-31
4. Bluming AZ, Ziegler JL. Regression of Burkitt's lymphoma in association with measles infection. Lancet 1971;2(7715):105-6
5. Gross S. Measles and leukaemia. Lancet 1971;1(7695):397-8
6. Mota HC. Infantile Hodgkin's disease: remission after measles. Br Med J 1973;2(5863):421
7. Pasquinucci G. Possible effect of measles on leukaemia. Lancet 1971;1(7690):136
8. Zygiert Z. Hodgkin's disease: remissions after measles. Lancet 1971;1(7699):593
9. Taqi AM, Abdurrahman MB, Yakubu AM, Fleming AF. Regression of Hodgkin's disease after measles. Lancet 1981;1(8229):1112
10. Ziegler JL. Spontaneous remission in Burkitt's lymphoma. Natl Cancer Inst Monogr 1976;44:61-5
11. Baker JP. The first measles vaccine. Pediatrics 2011;128(3):435-7
12. Enders JF, Peebles TC. Propagation in tissue cultures of cytopathogenic agents from patients with measles. Proc Soc Exp Biol Med 1954;86(2):277-86
13. Ono N, Tatsuo H, Hidaka Y, et al. Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor. J Virol 2001;75(9):4399-401
14. Schneider U, von Messling V, Devaux P, Cattaneo R. Efficiency of measles virus entry and dissemination through different receptors. J Virol 2002;76(15):7460-7
15. Navaratnarajah CK, Leonard VH, Cattaneo R. Measles virus glycoprotein complex assembly, receptor attachment, and cell entry. Curr Top Microbiol Immunol 2009;329:59-76
16. Vongpunsawad S, Oezgun N, Braun W, Cattaneo R. Selectively receptor-blind measles viruses: identification of residues necessary for SLAM-or CD46-induced fusion and their localization on a new hemagglutinin structural model. J Virol 2004;78(1):302-13
17. Muhlebach MD, Mateo M, Sinn PL, et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 2011;480(7378):530-3
18. Noyce RS, Bondre DG, Ha MN, et al. Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog 2011;7(8):e1002240
19. Yanagi Y, Takeda M, Ohno S. Measles virus: cellular receptors, tropism and pathogenesis. J Gen Virol 2006;87(Pt 10):2767-79
20. Muhlebach MD, Schaser T, Zimmermann M, et al. Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase- activatable oncolytic measles virus. Cancer Res 2010;70(19):7620-9
21. Dhiman N, Jacobson RM, Poland GA. Measles virus receptors: SLAM and CD46. Rev Med Virol 2004;14(4):217-29
22. Navaratnarajah CK, Oezguen N, Rupp L, et al. The heads of the measles virus attachment protein move to transmit the fusion-triggering signal. Nat Struct Mol Biol 2011;18(2):128-34
23. Wild TF, Malvoisin E, Buckland R. Measles virus: both the haemagglutinin and fusion glycoproteins are required for fusion. J Gen Virol 1991;72(Pt 2):439-42
24. Peng KW, Facteau S, Wegman T, et al. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med 2002;8(5):527-31
25. Dingli D, Peng KW, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004;103(5):1641-6
26. Phuong LK, Allen C, Peng KW, et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 2003;63(10):2462-9
27. Peng KW, Ahmann GJ, Pham L, et al. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 2001;98(7):2002-7
28. Galanis E, Bateman A, Johnson K, et al. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum Gene Ther 2001;12(7):811-21
29. Ebert O, Shinozaki K, Kournioti C, et al. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res 2004;64(9):3265-70
30. Guedan S, Grases D, Rojas JJ, et al. GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution. Gene Ther 2011;19(11):1048-57
31. Fu X, Tao L, Jin A, et al. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther 2003;7(6):748-54
32. Jurianz K, Ziegler S, Garcia-Schuler H, et al. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 1999;36(13-14):929-39
33. Fishelson Z, Donin N, Zell S, et al. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003;40(2-4):109-23
34. Anderson BD, Nakamura T, Russell SJ, Peng KW. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 2004;64(14):4919-26
35. Peng KW, Donovan KA, Schneider U, et al. Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood 2003;101(7):2557-62
36. Blechacz B, Splinter PL, Greiner S, et al. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology 2006;44(6):1465-77
37. Liu C, Erlichman C, McDonald CJ, et al. Heat shock protein inhibitors increase the efficacy of measles virotherapy. Gene Ther 2008;15(14):1024-34
38. Reymond N, Fabre S, Lecocq E, et al. Nectin4/PRR4, a new afadin-associated member of the nectin family that trans-interacts with nectin1/PRR1 through V domain interaction. J Biol Chem 2001;276(46):43205-15
39. Noyce RS, Richardson CD. Nectin 4 is the epithelial cell receptor for measles virus. Trends Microbiol 2012;20(9):429-39
40. Takano A, Ishikawa N, Nishino R, et al. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res 2009;69(16):6694-703
41. Derycke MS, Pambuccian SE, Gilks CB, et al. Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. Am J Clin Pathol 2010;134(5):835-45
42. Fabre-Lafay S, Monville F, Garrido-Urbani S, et al. Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer 2007;7:73
43. Russell SJ, Peng KW. Measles virus for cancer therapy. Curr Top Microbiol Immunol 2009;330:213-41
44. Ong HT, Timm MM, Greipp PR, et al. Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol 2006;34(6):713-20
45. Naik S, Russell SJ. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther 2009;9(9):1163-76
46. Bellini WJ, Rota PA. Genetic diversity of wild-type measles viruses: implications for global measles elimination programs. Emerg Infect Dis 1998;4(1):29-35
47. Griffin DE, Pan CH. Measles: old vaccines, new vaccines. Curr Top Microbiol Immunol 2009;330:191-212
48. Nakamura T, Peng KW, Harvey M, et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 2005;23(2):209-14
49. Billeter MA, Naim HY, Udem SA. Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses. Curr Top Microbiol Immunol 2009;329:129-62
50. McQuillan GM, Kruszon-Moran D, Hyde TB, et al. Seroprevalence of measles antibody in the US population, 1999-2004. J Infect Dis 2007;196(10):1459-64
51. Radecke F, Spielhofer P, Schneider H, et al. Rescue of measles viruses from cloned DNA. Embo J 1995;14(23):5773-84
52. Duprex WP, McQuaid S, Hangartner L, et al. Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J Virol 1999;73(11):9568-75
53. Peng KW, TenEyck CJ, Galanis E, et al. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 2002;62(16):4656-62
54. Iankov ID, Hillestad ML, Dietz AB, et al. Converting tumor-specific markers into reporters of oncolytic virus infection. Mol Ther 2009;17(8):1395-403
55. Ungerechts G, Springfeld C, Frenzke ME, et al. Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res 2007;67(22):10939-47
56. Ungerechts G, Springfeld C, Frenzke ME, et al. An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther 2007;15(11):1991-7
57. Li H, Peng KW, Dingli D, et al. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther 2010;17(8):550-8
58. Galanis E, Hartmann LC, Cliby WA, et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 2010;70(3):875-82
59. Tan E, Gouvas N, Nicholls RJ, et al. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol 2009;18(1):15-24
60. Hingorani M, Spitzweg C, Vassaux G, et al. The biology of the sodium iodide symporter and its potential for targeted gene delivery. Curr Cancer Drug Targets 2010;10(2):242-67
61. Penheiter AR, Russell SJ, Carlson SK. The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies. Curr Gene Ther 2012;12(1):33-47
62. Dingli D, Bergert ER, Bajzer Z, et al. Dynamic iodide trapping by tumor cells expressing the thyroidal sodium iodide symporter. Biochem Biophys Res Commun 2004;325(1):157-66
63. Dingli D, Russell SJ, Morris JC III. In vivo imaging and tumor therapy with the sodium iodide symporter. J Cell Biochem 2003;90(6):1079-86
64. Hasegawa K, Pham L, O'Connor MK, et al. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin Cancer Res 2006;12(6):1868-75
65. Peng KW, Frenzke M, Myers R, et al. Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice. Hum Gene Ther 2003;14(16):1565-77
66. Allen C, Paraskevakou G, Liu C, et al. Oncolytic measles virus strains in the treatment of gliomas. Expert Opin Biol Ther 2008;8(2):213-20
67. Myers R, Harvey M, Kaufmann TJ, et al. Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas. Hum Gene Ther 2008;19(7):690-8
68. Myers RM, Greiner SM, Harvey ME, et al. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 2007;82(6):700-10
69. Myers RM, Harvey ME, Greiner SM, et al. Safety of repeat intracerebral administration of MV-CEA in Rhesus macaques in support of a Phase I/II Clinical Trial for patients with recurrent gliomas (abstract 297). Mol Ther 2006;13(suppl 1):s113
70. Kemper C, Leung M, Stephensen CB, et al. Membrane cofactor protein (MCP; CD46) expression in transgenic mice. Clin Exp Immunol 2001;124(2):180-9
71. Mrkic B, Odermatt B, Klein MA, et al. Lymphatic dissemination and comparative pathology of recombinant measles viruses in genetically modified mice. J Virol 2000;74(3):1364-72
72. Mrkic B, Pavlovic J, Rulicke T, et al. Measles virus spread and pathogenesis in genetically modified mice. J Virol 1998;72(9):7420-7
73. Allen C, Paraskevakou G, Liu C, et al. Oncolytic measles virus strains in the treatment of gliomas. Expert Opin Biol Ther 2008;8(2):213-20
74. Hsu EC, Dorig RE, Sarangi F, et al. Artificial mutations and natural variations in the CD46 molecules from human and monkey cells define regions important for measles virus binding. J Virol 1997;71(8):6144-54
75. Kobune F, Takahashi H, Terao K, et al. Nonhuman primate models of measles. Lab Anim Sci 1996;46(3):315-20
76. Allen C, Msaouel P, Aderca I, et al. Optimizing the antitumor activity of engineered measles virus strains in the treatment of gliomas. Mol Ther 2009;17(Suppl 1):S108
77. Cerullo V, Diaconu I, Kangasniemi L, et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther 2011;19(9):1737-46
78. Lun XQ, Jang JH, Tang N, et al. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res 2009;15(8):2777-88
79. Peng KW, Myers R, Greenslade A, et al. Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. Gene Ther 2012; Epub ahead of print
80. Qiao J, Wang H, Kottke T, et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 2008;14(1):259-69
81. NCT00450814: vaccine therapy with or without cyclophosphamide in treating patients with recurrent or refractory multiple myeloma. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00450814
82. Heinzerling L, Kunzi V, Oberholzer PA, et al. Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood 2005;106(7):2287-94
83. Msaouel P, Dispenzieri A, Galanis E. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther 2009;11(1):43-53
84. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-16
85. Markman M, Webster K, Zanotti K, et al. Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. Gynecol Oncol 2004;93(3):699-701
86. NCT00408590: recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00408590
87. NCT00390299: viral therapy in treating patients with recurrent glioblastoma multiforme. Available from: http://www. clinicaltrials.gov/ct2/ show/NCT00390299
88. NCT01503177: Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma. Available from: http://www.clinicaltrials. gov/show/NCT01503177
89. Allen C, Paraskevakou G, Iankov I, et al. Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. Mol Ther 2008;16(9):1556-64
90. Paraskevakou G, Allen C, Nakamura T, et al. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR-or EGFRvIII expressing gliomas. Mol Ther 2007;15(4):677-86
91. Hallak LK, Merchan JR, Storgard CM, et al. Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression. Cancer Res 2005;65(12):5292-300
92. Ong HT, Trejo TR, Pham LD, et al. Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo. Mol Ther 2009;17(6):1012-21
93. Jing Y, Tong C, Zhang J, et al. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. Cancer Res 2009;69(4):1459-68
94. Allen C, Vongpunsawad S, Nakamura T, et al. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res 2006;66(24):11840-50
95. Hasegawa K, Nakamura T, Harvey M, et al. The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res 2006;12(20 Pt 1):6170-8
96. Hasegawa K, Hu C, Nakamura T, et al. Affinity thresholds for membrane fusion triggering by viral glycoproteins. J Virol 2007;81(23):13149-57
97. Hummel HD, Kuntz G, Russell SJ, et al. Genetically engineered attenuated measles virus specifically infects and kills primary multiple myeloma cells. J Gen Virol 2009;90(Pt 3):693-701
98. Nakamura T, Peng KW, Vongpunsawad S, et al. Antibody-targeted cell fusion. Nat Biotechnol 2004;22(3):331-6
99. Leonard VH, Sinn PL, Hodge G, et al. Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed. J Clin Invest 2008;118(7):2448-58
100. Schneider U, Bullough F, Vongpunsawad S, et al. Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol 2000;74(21):9928-36
101. Msaouel P, Iankov ID, Allen C, et al. Oncolytic measles virus retargeting by ligand display. Methods Mol Biol 2012;797:141-62
102. Springfeld C, von Messling V, Frenzke M, et al. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res 2006;66(15):7694-700
103. Maisner A, Mrkic B, Herrler G, et al. Recombinant measles virus requiring an exogenous protease for activation of infectivity. J Gen Virol 2000;81(Pt 2):441-9
104. Leber MF, Bossow S, Leonard VH, et al. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism. Mol Ther 2011;19(6):1097-106
105. Kefas B, Godlewski J, Comeau L, et al. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 2008;68(10):3566-72
106. Webster RJ, Giles KM, Price KJ, et al. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 2009;284(9):5731-41
107. Liu YP, Tong C, Dispenzieri A, et al. Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus. Cancer Gene Ther 2012;19(3):202-11
108. Iankov ID, Blechacz B, Liu C, et al. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther 2007;15(1):114-22
109. Liu C, Russell SJ, Peng KW. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther 2010;18(6):1155-64
110. Ordman CW, Jennings CG, Janeway CA. Chemical, clinical, and immunological studies on the products of human plasma fractionation. xii. The use of concentrated normal human serum gamma globulin (human immune serum globulin) in the prevention and attenuation of measles. J Clin Invest 1944;23(4):541-9
111. Zingher A, Mortimer P. Convalescent whole blood, plasma and serum in the prophylaxis of measles: JAMA, 12 April, 1926; 1180-1187. Rev Med Virol 2005;15(6):407-18; discussion 18-21
112. Iankov ID, Msaouel P, Allen C, et al. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast Cancer Res Treat 2009;122(3):745-54
113. Ong HT, Hasegawa K, Dietz AB, et al. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther 2007;14(4):324-33
114. Peng KW, Dogan A, Vrana J, et al. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. Am J Hematol 2009;84(7):401-7
115. Mader EK, Maeyama Y, Lin Y, et al. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res 2009;15(23):7246-55
116. Wei J, Wahl J, Nakamura T, et al. Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas. Gene Ther 2007;14(22):1573-86
117. Miest TS, Yaiw KC, Frenzke M, et al. Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis. Mol Ther 2011;19(10):1813-20
118. de Vries RD, Mesman AW, Geijtenbeek TB, et al. The pathogenesis of measles. Curr Opin Virol 2012;2(3):248-55
119. Haralambieva I, Iankov I, Hasegawa K, et al. Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Mol Ther 2007;15(3):588-97
120. Meng X, Nakamura T, Okazaki T, et al. Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma. Mol Ther 2010;18(3):544-51
121. Shaffer JA, Bellini WJ, Rota PA. The C protein of measles virus inhibits the type I interferon response. Virology 2003;315(2):389-97
122. Takeuchi K, Kadota SI, Takeda M, et al. Measles virus V protein blocks interferon (IFN)-alpha/beta but not IFN-gamma signaling by inhibiting STAT1 and STAT2 phosphorylation. FEBS Lett 2003;545(2-3):177-82
123. Devaux P, von Messling V, Songsungthong W, et al. Tyrosine 110 in the measles virus phosphoprotein is required to block STAT1 phosphorylation. Virology 2007;360(1):72-83
124. Bankamp B, Takeda M, Zhang Y, et al. Genetic characterization of measles vaccine strains. J Infect Dis 2011;204(Suppl 1):S533-48
125. Prestwich RJ, Errington F, Diaz RM, et al. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther 2009;20(10):1119-32
126. Gauvrit A, Brandler S, Sapede-Peroz C, et al. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res 2008;68(12):4882-92
127. Zhang Y, Patel B, Dey A, et al. Attenuated, oncolytic, but not wild-type measles virus infection has pleiotropic effects on human neutrophil function. J Immunol 2012;188(3):1002-10
128. Eager R, Nemunaitis J. GM-CSF gene-transduced tumor vaccines. Mol Ther 2005;12(1):18-27
129. Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol 2006;24(5):419-24
130. Grote D, Cattaneo R, Fielding AK. Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Res 2003;63(19):6463-8
131. Richard C, Baro J, Bello-Fernandez C, et al. Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) administration after autologous bone marrow transplantation for acute myeloblastic leukemia enhances activated killer cell function and may diminish leukemic relapse. Bone Marrow Transplant 1995;15(5):721-6
132. Gupta R, Emens LA. GM-CSF-secreting vaccines for solid tumors: moving forward. Discov Med 2010;10(50):52-60
133. Bracarda S, Eggermont AM, Samuelsson J. Redefining the role of interferon in the treatment of malignant diseases. Eur J Cancer 2010;46(2):284-97
134. Satin B, Del Giudice G, Della Bianca V, et al. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J Exp Med 2000;191(9):1467-76
135. Montemurro P, Barbuti G, Dundon WG, et al. Helicobacter pylori neutrophil-activating protein stimulates tissue factor and plasminogen activator inhibitor-2 production by human blood mononuclear cells. J Infect Dis 2001;183(7):1055-62
136. Iankov ID, Allen C, Federspiel MJ, et al. Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus. Mol Ther 2012;20(6):1139-47
137. Liu C, Sarkaria JN, Petell CA, et al. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin Cancer Res 2007;13(23):7155-65
138. Schwartz M. A biomathematical approach to clinical tumor growth. Cancer 1961;14:1272-94
139. Msaouel P, Iankov ID, Allen C, et al. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther 2009;17(12):2041-8
140. Opyrchal M, Allen C, Iankov I, et al. Effective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter (MV-NIS). Hum Gene Ther 2012;23(4):419-27
141. Li H, Peng KW, Russell SJ. Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy. Hum Gene Ther 2012;23(3):295-301
142. Reddi HV, Madde P, McDonough SJ, et al. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy. Cancer Gene Ther 2012;19(9):659-65
143. Penheiter AR, Wegman TR, Classic KL, et al. Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer. AJR Am J Roentgenol 2010;195(2):341-9
144. Ungerechts G, Frenzke ME, Yaiw KC, et al. Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics. Gene Ther 2010;17(12):1506-16
145. Opyrchal M, Iankov I, Allen C, Galanis E. Inhibition of rho associated coiled-coil forming kinase increases efficacy of measles virus infection. Molecular Therapy 2011;19(suppl 1):s142 (abstract 365).
146. Parrula C, Fernandez SA, Zimmerman B, et al. Measles virotherapy in a mouse model of adult T cell leukemia/lymphoma. J Gen Virol 2011;92(Pt 6):1458-66
147. Langfield KK, Walker HJ, Gregory LC, Federspiel MJ. Manufacture of measles viruses. Methods Mol Biol 2011;737:345-66
148. Grote D, Russell SJ, Cornu TI, et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001;97(12):3746-54
149. Bucheit AD, Kumar S, Grote DM, et al. An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther 2003;7(1):62-72
150. Patel B, Dey A, Ghorani E, et al. Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights. Mol Ther 2011;19(6):1034-40
151. Yaiw KC, Miest TS, Frenzke M, et al. CD20-targeted measles virus shows high oncolytic specificity in clinical samples from lymphoma patients independent of prior rituximab therapy. Gene Ther 2011;18(3):313-17
152. Kunzi V, Oberholzer PA, Heinzerling L, et al. Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo. J Invest Dermatol 2006;126(11):2525-32
153. Peng KW, Holler PD, Orr BA, et al. Targeting virus entry and membrane fusion through specific peptide/MHC complexes using a high-affinity T-cell receptor. Gene Ther 2004;11(15):1234-9
154. Zhou S, Li Y, Huang F, et al. Live-attenuated measles virus vaccine confers cell contact loss and apoptosis of ovarian cancer cells via ROS-induced silencing of E-cadherin by methylation. Cancer Lett 2012;318(1):14-25
155. McDonald CJ, Erlichman C, Ingle JN, et al. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res Treat 2006;99(2):177-84
156. Sugiyama T, Yoneda M, Kuraishi T, et al. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment. Gene Ther 2012; [Epub ahead of print]
157. Zimmermann M, Armeanu S, Smirnow I, et al. Human precision-cut liver tumor slices as a tumor patient-individual predictive test system for oncolytic measles vaccine viruses. Int J Oncol 2009;34(5):1247-56
158. Hammond AL, Plemper RK, Zhang J, et al. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol 2001;75(5):2087-96
159. Msaouel P, Iankov ID, Allen C, et al. Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate 2009;69(1):82-91
160. Liu C, Hasegawa K, Russell SJ, et al. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate 2009;69(10):1128-41
161. Carlson SK, Classic KL, Hadac EM, et al. In vivo quantitation of intratumoral radioisotope uptake using micro-single photon emission computed tomography/computed tomography. Mol Imaging Biol 2006;8(6):324-32
162. Carlson SK, Classic KL, Hadac EM, et al. Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene. AJR Am J Roentgenol 2009;192(1):279-87
163. Bossow S, Grossardt C, Temme A, et al. Armed and targeted measles virus for chemovirotherapy of pancreatic cancer. Cancer Gene Ther 2011;18(8):598-608
164. Penheiter AR, Griesmann GE, Federspiel MJ, et al. Pinhole micro-SPECT/CT for noninvasive monitoring and quantitation of oncolytic virus dispersion and percent infection in solid tumors. Gene Ther 2012;19(3):279-87
165. Donnelly OG, Errington-Mais F, Steele L, et al. Measles virus causes immunogenic cell death in human melanoma. Gene Ther 2011; [Epub ahead of print]
166. Studebaker AW, Kreofsky CR, Pierson CR, et al. Treatment of medulloblastoma with a modified measles virus. Neuro Oncol 2010;12(10):1034-42
167. Studebaker AW, Hutzen B, Pierson CR, et al. Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluid-disseminated medulloblastoma. Neuro Oncol 2012;14(4):459-70 Institute Institute Institute Institute